Context Therapeutics Inc. (CNTX)
Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 20260 patents granted to the name below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Context Therapeutics Inc.’s names, not what it holds today.
4 published
| Published | Application | Title | Field | Owner as printed |
|---|---|---|---|---|
| Oct 30, 2025 | 2025/0333499 | BISPECIFIC ANTIBODIES AND METHODS OF USING THE SAME | Biotechnology | Context Therapeutics Inc. |
| Oct 30, 2025 | 2025/0332255 | COMPOSITIONS COMPRISING BISPECIFIC ANTIBODIES THAT BIND TO CLAUDIN 6 AND CD3, AND USES THEREOF | Pharmaceuticals | Context Therapeutics Inc. |
| Aug 1, 2024 | 2024/0254561 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | Pharmaceuticals | Context Therapeutics Inc. |
| Mar 19, 2020 | 2020/0087730 | METHODS OF IDENTIFYING AND TREATING TUMORS WITH SIGMA1 INHIBITORS | Pharmaceuticals | Context Therapeutics Inc. |
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.